Drug intelligence / Profile preview

SVF-005

Development stage: Preclinical
Lead developer: SVF Vaccines
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous, Intraarticular, Intrathecal, Epidural, Soft Tissue, Spinal

Overview

SVF-005 is an investigational vaccine candidate currently in preclinical development by SVF Vaccines for the prevention of malaria. The vaccine utilizes a dual-platform approach, incorporating both DNA and mRNA vaccine technologies to stimulate a protective immune response against malaria-causing parasites. As part of SVF Vaccines' pipeline, SVF-005 aims to address the global burden of malaria by leveraging advanced nucleic acid delivery systems to deliver genetic sequences encoding for pathogen-specific antigens.

Beyond the preview

Go deeper on SVF-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVF-005.

Explore the full profile